 Home > Active Ingredient News > Drugs Articles > 【First Offering】Huawei Hengyuan completed tens of millions of Pre-A+ round financing to accelerate the clinical application of the immunization exemption pipeline

【First Offering】Huawei Hengyuan completed tens of millions of Pre-A+ round financing to accelerate the clinical application of the immunization exemption pipeline

 Last Update: 2023-01-01
 Source: Internet
 Author: User

Tags

blue based red

beauty industry trends

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Arterial New Medicine learned for the first time that recently, Huawei Hengyuan (Beijing) Biomedical Technology Co.
, Ltd.
(hereinafter referred to as "Huawei Hengyuan") completed tens of millions of pre-A+ round financing, this round of financing led by Danlu Capital, Ruisheng Investment, Yuanhe Capital and other new shareholders followed
.
It is reported that the funds raised in this round will be mainly used for safety verification, process development and clinical declaration of Huawei Hengyuan's core pipeline, subsequent expansion of production bases and talent recruitment
.

Huawei Hengyuan (Beijing) Biomedical Technology Co.
, Ltd.
(hereinafter referred to as "Huawei Hengyuan") completed tens of millions of Pre-A+ round financing, led by Danlu Capital, and followed by new shareholders such as Ruisheng Investment and Yuanhe Capital
.
It is reported that the funds raised in this round will be mainly used for safety verification, process development and clinical declaration of Huawei Hengyuan's core pipeline, subsequent expansion of production bases and talent recruitment
.

Founded at the end of 2018, Huawei Hengyuan is a biomedical enterprise
committed to creating a new artificial immune immunity microenvironment and clinical transformation application platform to solve the problems of immune rejection and male infertility in the field of regenerative medicine.
Since its establishment, Huawei Hengyuan has completed a total of three rounds of financing
.
Previously, Huawei Hengyuan has also been recognized
by Shuimu Venture Capital, TusStar Venture Capital, Huaan Jingyin, Jiuhe Venture Capital and other capitals.

From Tsinghua Technology,

Basic research results are moving towards clinical transformation

"This technology patent is the result
of your research during your doctoral studies.
If you have the opportunity to translate it and successfully apply it to the clinic, it will distinguish it from the sense of
accomplishment that comes with other successes in your life.
”

It is precisely because of the words of his supervisor, Professor Ji Jiakui, that Dr.
Liang Jianlin decisively chose the path
of entrepreneurship after graduation.
However, entrepreneurship is not an easy task, and the success of Huawei Hengyuan today is inseparable
from the three elements of "people, time and location".

In terms of "people", Professor Ji Jiakui and Dr.
Liang Jianlin are typical university teachers and students cooperative entrepreneurship model
.
Before the establishment of Huawei Hengyuan, the two had many years of
experience in scientific research project cooperation.

On "people and people",

As the founder of Huawei Hengyuan, Dr.
Liang is the inventor of the company's core patent human immune immune immune cell induction technology, and has nearly ten years of research experience
in human stem cells, reproductive development and immune immunity mechanism.
As the chief scientist of the company, Professor Ji is not only the inventor of human immunity-free cell induction technology, but also a well-known scientist in the field of stem cell and regenerative medicine, and is currently the deputy director and long-term professor of the Department of Basic Medicine of Tsinghua University School of Medicine.

In terms of "Tianshi", Dr.
Leung Jianlin chose to start a business, not only because Professor Ji's seat made him empowered, but also because his graduation was also the time when
his scientific research achievements were polished and matured.
In addition, the development of the domestic CGT industry in those years was also in full swing
.

In terms of "time of day",

Dr.
Liang said frankly, "Such a suitable time node for transformation is fleeting, and if this technology is not transformed after two years, it may fall behind; If it is handed over to others to transform at that time, it is difficult to persuade others to support a new technology
wholeheartedly.
For various reasons, Dr.
Liang decided to take the lead in advancing this technology
.

Huawei Hengyuan's advantages in "geographical advantage" are also obvious: the company is deeply rooted in Tsinghua's industrial soil
.

Compared with other start-ups, Huawei Hengyuan has backed Tsinghua at the beginning of its establishment, and has the venue and equipment resources, policy resources, industry docking resources and talent resources
brought by top domestic universities.
At the beginning of its establishment, the two founders of Huawei Hengyuan were both scientists and lacked mature experience
in enterprise operation and industrialization.
With the help of Tsinghua Technology Transfer Institute and Tsinghua Institute of Technology and Research Institute, through industrial docking, the company reached cooperation with Tsinghua funds such as Shuimu Venture Capital at the beginning of its establishment, and met industry insiders and investors through investment institutions
.
In the process of development, it has successively obtained the empowerment of industrial resources such as Enlighten Star and Global Health Industry Innovation Center
.

So far, Huawei Hengyuan has a talent team
covering the whole process of front-end scientific research technology development, product process development, clinical transformation, enterprise operation and quality control.

Immune exemption technology solves the bottleneck of regenerative medicine,

Synchronously promote the industrialization process of the three pipelines

With the dual blessing of talents and funds, Huawei Hengyuan aims at the current common pain points in the field of regenerative medicine: immune rejection and male infertility
.

Immune rejection is the main obstacle faced by cell tissue transplantation, and it is the primary factor that causes the failure of allogeneic transplantation such as islet cells, liver cells and immune fines in clinical practice.

Immune rejection can also induce autoimmune diseases, such as rheumatoid arthritis, goiter and other chronic underlying diseases
.

In response to this pain point, Huawei Hengyuan developed a human-derived immune immune cell induction technology
based on iPSC cells.

Testicular Sertoli cells belong to a special class of gonadal cells, with immune immunity and reproductive support capabilities, which can just solve the common immune rejection and male infertility pain points
in the industry.
Clinically, Sertoli cells can be used as immune immunity vectors to protect allogeneic transplanted cells, avoid HLA matching restrictions, expand the range of transplanted donors, or repair the microenvironment
at the site of immune dysregulation.
In addition, the cells can also be used to treat severe azoospermia and repair the damaged spermatogenic environment
.

This technology is the first to realize the in vitro induction of human immunity-exempt cells, and is highly versatile, and can be applied to a variety of diseases and drug development
.
Focusing on the core technology, Huawei Hengyuan has successfully built a pluripotent stem cell editing and directed differentiation platform and an immune immune cell transplantation protection vector (general-purpose) platform
.

Based on the universal platform, the company currently lays out three major disease areas
: autoimmune diseases, male assisted reproduction, and cell transplantation treatment.
In the future, Huawei Hengyuan will not only consider the R&D and industrialization of cell therapy products, but also help more CGT pharmaceutical companies in the industry to establish a full-process quality control evaluation system based on the universality of Sertoli cells and break through the bottleneck
of immune rejection.

Huawei Hengyuan will not only consider the R&D and industrialization of cell therapy products, but also help more CGT pharmaceutical companies in the industry to establish a full-process quality control evaluation system based on the universality of Sertoli cells and break through the bottleneck
of immune rejection.

At present, Huawei Hengyuan has three core pipelines
.
The fastest progressing rheumatoid arthritis pipeline is expected to enter the clinical filing stage soon; The cell transplantation pipeline has completed the proof-of-concept of the diabetes project and achieved good animal experimental results; For the male azoospermia pipeline, the company has developed a prototype of the front-end kit and completed the classification definition, and is currently preparing the registration and production
of related IVD products.

In order to promote the industrialization process of pipelines, Huawei Hengyuan currently has a 300-square-meter R&D and transformation laboratory, equipped with fluorescence microscopes, centrifuges, incubators, biological safety cabinets and other full-chain cell process equipment, and has established a whole-process quality management system
.
After this financing, the company plans to build a production base
of 2,000 square meters.

In terms of market accessibility of future products, Huawei Hengyuan also has its own innate advantages: its products have universal prices
.

The price of CGT products is indeed a problem that cannot be ignored at present, in terms of reducing costs, Huawei Hengyuan adopts a universal production method, "Why can we achieve universal production?" This is closely related
to the properties of Sertoli cells.
Sertoli cells themselves have immune immunity function, so its cell therapy products are not divided into autologous and allogeneic, and its production process is relatively simple and easy to achieve standardized production
.
”

It is expected that Huawei Hengyuan will take the development of new cell drugs as the core, establish more products in the field of indications around immune immunity technology, and cooperate with the industry to break through the bottleneck of regenerative medicine and attack a broader pharmaceutical blue ocean
.

Businesses say & investors say

Liang Jianlin, CEO & co-founder of Huawei Hengyuan, said: This round of financing was basically over
in the first half of the year.
At present, in the cold winter of capital and the general confusion in the biomedical field, Huawei Hengyuan has been able to successfully complete the PreA+ round of financing and carry out a global layout, thanks to the uniqueness and platform of the company's disruptive technologies by the new shareholders and previous shareholders in this round; Execution and innovation of the company's robust team; Recognition
of the progress of the company's core pipeline and R&D strength.
Here, we would like to express our sincere gratitude to our new and existing shareholders for their continued support
.

Liang Jianlin, CEO & co-founder of Huawei Hengyuan

"The vicissitudes of the sea, the true colors of heroes are revealed, the green mountains stand, and the aspiration of not falling into the clouds"
.
As a cell drug company, especially an enterprise deeply engaged in the field of iPSC and mastering the autoimmune exemption technology, Huawei Hengyuan adheres to the bottom line of "safe and effective", and the company always treats product development
with humility and awe.
Solidly make the process module and curative effect mechanism sufficient and sufficient to ensure the stability and safety
of the product.
Huawei Hengyuan firmly believes that only the products produced in this way are responsible products for patients; Only such an enterprise is a promising enterprise
.

At present, Huawei Hengyuan has gradually established a perfect production quality management system and passed the corresponding qualification certification, and after being selected as a subversive project in Guancun in 2020, it was successfully approved as a postdoctoral research workstation
of the Ministry of Human Resources and Social Security this year.
In the future, Huawei Hengyuan will continue to develop pipeline products in the field of transplant rejection and male infertility around the original subversive platform technology of human immune immunity, and simultaneously establish a globally authorized immune immunity transplant protection vector platform
.

Lu Qinchao, partner of Danlu Capital, said: Huawei Hengyuan has mastered the exclusive in vitro induction technology
of human Sertoli cells.
Sertoli cells can not only be used as an ideal protective vehicle for transplanted cells and tissues, for repairing the microenvironment of immune dysregulated sites, but also for the treatment
of severe azoospermia in men.
Therefore, the company's core technology can be applied to a variety of disease fields, and the market potential is huge; Professor Ji Jiakui is a well-known expert in the field of stem cell differentiation and germ cells, and his team has been deeply engaged in this field for many years and has achieved breakthrough results in many important pipelines.
We are very pleased to work with this excellent team and hope to help Huawei Hengyuan become a leading international biopharmaceutical company
.
"

Qinchao Lu, partner of Danlu Capital

Ling Ling, Investment Director of Ruisheng Investment, said: "The CGT industry is the main track for China's biomedical industry to achieve curve overtaking, and the cell therapy platform technology based on iPSC is expected to achieve breakthrough efficacy
in the medical market that currently lacks effective treatment methods.
The Huawei Hengyuan team has formulated a clear cell therapy enterprise development strategy, the company is based on the international first human immune immunity cell technology with completely independent intellectual property rights, rheumatoid arthritis cell injection, immune immune artificial pancreas and assisted reproductive detection system and other product pipelines are in line with expectations
。 Ruisheng Investment will, as always, rely on the Inno.
EcoS service ecology of Zhongguancun Dongsheng Science and Technology Park, focus on the industrial innovation service system of Huawei Hengyuan enterprises and talents, start from the needs of enterprises, continuously improve the enterprise growth ecosystem, open up the full life cycle service chain of enterprises, and provide tailored services
for the company's growth and maturity.

Ling Ling, Investment Director of Ruisheng Investment

Zhang Jianyao, investment director of Yuanhe Capital, said: Since the birth of modern medicine, the contradiction between the demand for in vitro transplantation and the serious shortage of donors caused by the aging, lesion and damage of organs and cells has plagued the entire industry
.
Regenerative medicine is not only expected to solve the problem of insufficient donors, but also can effectively and fully improve the utilization efficiency of donated organs, which has incalculable social and commercial value
.
Huawei Hengyuan's unique human-derived immune immune cell induction technology can realize the large-scale induction of human immune immune cells, and is applied to the field of self-immune diseases and cell transplantation, solving the problem of immune rejection of cell transplantation, and has a wide range of application prospects
.
The technical strength of Huawei Hengyuan in the field of immune exempt cells is obvious to all, and the broad application prospects and high technical threshold are the great advantages
of Huawei Hengyuan.

Zhang Jianyao, Investment Director of Yuanhe Capital

About Danlu Capital

Founded in early 2018 by former Sequoia Capital China Fund Partner Qinchao Lu and former Sharing Investment Managing Partner Su Zhenbo, Danlu Capital is a venture capital firm focusing on the healthcare industry, systematically deploying innovative medical technologies such as high-value consumables, in vitro diagnostic reagents, consumer healthcare, digital healthcare, as well as innovative drugs and new medical services
。 Danlu Capital is committed to rewarding investors with excellent performance, and hopes to use the power of capital to accelerate the research and development and marketization of modern medical and pharmaceutical technology, so as to improve the level of national medical health and become a trustworthy and evergreen excellent medical fund management company
.
"Climb up, Danlu is always on the road"
.
As the "shoulder" of entrepreneurs and investors, Danlu Capital is deeply engaged in the fields of innovative medical technology, innovative drugs and medical services, and is committed to becoming a trustworthy and influential medical venture capital institution, climbing to the peak
of career together with entrepreneurs.

About meta and capital

Founded in 2016, Yuanhe Capital is an early-stage VC fund with both a fund of funds and a direct investment fund, and the sub-fund stage invested by the fund of funds covers the seed stage to the B round
.
Yuanhe Capital uses the fund of funds as the platform and early angel investment as the entrance
.
Adhering to the concept of "working with excellence and creating a better future", as of 2022, Yuanhe Capital has issued three fund of funds and two direct investment funds, committed to establishing an equity investment industry chain ecology, and actively exploring the best path
of "double innovation" and "industrial development" 。 The company mainly serves two ends: the front-end serves entrepreneurial projects, and Yuanhe Capital will work together with excellent fund institutions to condense the wealth, rich experience and precipitated resources accumulated by mature entrepreneurs, provide multi-party support for the healthy growth of start-ups, establish and improve the early and mid-term venture capital ecology, continuously innovate, continuously improve user experience, achieve great scientific and technological innovation companies, and contribute to the construction of an "innovative country"; The back-end serves industrial capital, the core is listed companies, Yuanhe Capital will help industrial capital to discover opportunities for industrial synergy, provide value-added services, use capital to help industrial transformation and upgrading, and achieve good equity investment returns
.

About Ruisheng Investment

Ruisheng Investment relies on the platform resources and industrial aggregation advantages of Zhongguancun Dongsheng Science and Technology Park to create a full-chain investment system
.
In terms of medical and health care, relying on the layout of the health industry of Dongsheng Science and Technology Park and the professional funds of biomedicine and medical devices invested abroad, we will focus on new medical technologies and products
that are high value, in the rising channel, with barriers or scarcity in the industry.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.